{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:07:42Z","timestamp":1794344862156,"version":"4.9.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T00:00:00Z","timestamp":1726012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xcrm.2024.101760","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T10:37:56Z","timestamp":1728383876000},"page":"101760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications"],"prefix":"10.1016","volume":"5","author":[{"given":"William A.","family":"Banks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Rhea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May J.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101760_bib1","first-page":"651","article-title":"Drug discovery and development: Role of basic biological research","volume":"3","author":"Mohs","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.xcrm.2024.101760_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1083\/jcb.34.1.207","article-title":"Fine structural localization of a blood-brain barrier to endogenous peroxidase","volume":"34","author":"Reese","year":"1967","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101760_bib3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1124\/pr.117.014647","article-title":"Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: Bases for physiological regulation, disease states, and pharmacological interventions","volume":"70","author":"Erickson","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib4","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41574-019-0213-7","article-title":"The blood-brain barrier as an endocrine tissue","volume":"15","author":"Banks","year":"2019","journal-title":"Nature Reviews Endocrinology"},{"key":"10.1016\/j.xcrm.2024.101760_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12987-023-00478-5","article-title":"Blood-brain borders: a proposal to address limitations of historical blood-brain barrier terminology","volume":"21","author":"Badaut","year":"2024","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.xcrm.2024.101760_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrd.2015.21","article-title":"From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery","volume":"15","author":"Banks","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.xcrm.2024.101760_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-Brain Barrier: From Physiology to Disease and Back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib8","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/s41593-021-00904-7","article-title":"Revisiting the neurovascular unit","volume":"24","author":"Schaeffer","year":"2021","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib9","series-title":"Opium Reality\u2019s Dark Dream","author":"Dormandy","year":"2012"},{"key":"10.1016\/j.xcrm.2024.101760_bib10","series-title":"Aspirin","author":"Jeffreys","year":"2004"},{"key":"10.1016\/j.xcrm.2024.101760_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1126\/science.178.4064.984","article-title":"Blood-brain barrier - penetration of morphine, codeine, heroin, and methadone after carotid injection","volume":"178","author":"Oldendorf","year":"1972","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101760_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fnins.2014.00404","article-title":"The rights and wrongs of blood-brain barrier permeability studies: a walk through 100 years of history","volume":"8","author":"Saunders","year":"2014","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/09647040601138478","article-title":"Science and fate: Lina Stern (1878-1968), a neurophysiologist and biochemist","volume":"17","author":"Vein","year":"2008","journal-title":"J.\u00a0Hist. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1039\/tf9373300985","article-title":"The permeability of plant protoplasts to nonelectrolytes","volume":"33","author":"Collander","year":"1937","journal-title":"Trans. Faraday Soc."},{"key":"10.1016\/j.xcrm.2024.101760_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3181\/00379727-147-38444","article-title":"Lipid solubility and drug penetration of the blood-brain barrier","volume":"147","author":"Oldendorf","year":"1974","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0361-9230(85)90153-4","article-title":"Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability","volume":"15","author":"Banks","year":"1985","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.xcrm.2024.101760_bib17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00000542-199210000-00020","article-title":"Physical and chemical properties of\u00a0drug molecules governing their diffusion through the spinal meninges","volume":"77","author":"Bernards","year":"1992","journal-title":"Anesthesiology"},{"key":"10.1016\/j.xcrm.2024.101760_bib18","first-page":"1030","article-title":"Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals","volume":"24","author":"Dischino","year":"1983","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/10611869808997889","article-title":"Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors","volume":"6","author":"van de Waterbeemd","year":"1998","journal-title":"J.\u00a0Drug Target."},{"key":"10.1016\/j.xcrm.2024.101760_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/292683","article-title":"A Genetic Algorithm Based Support Vector Machine Model for Blood-Brain Barrier Penetration Prediction","volume":"2015","author":"Zhang","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.xcrm.2024.101760_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and developmental settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib22","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1023\/A:1018969222130","article-title":"Hydrogen bonding potential as a determinant of the in\u00a0vitro and in\u00a0situ blood-brain barrier permeability of peptides","volume":"11","author":"Chikhale","year":"1994","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.xcrm.2024.101760_bib23","doi-asserted-by":"crossref","first-page":"C161","DOI":"10.1152\/ajpcell.1982.243.3.C161","article-title":"Comparison of lipid-mediated blood-brain-barrier penetrability in neonates and adults","volume":"243","author":"Cornford","year":"1982","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib24","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0022-3565(25)39468-1","article-title":"Assessment of an in\u00a0vitro blood-brain barrier model using several [Met 5 ]enkephalin opioid analogs","volume":"266","author":"Weber","year":"1993","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2024.101760_bib25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ejpb.2008.05.005","article-title":"Predicting blood-brain barrier penetration from molecular weight and number of polar atoms","volume":"70","author":"Fu","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.xcrm.2024.101760_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acschemneuro.9b00541","article-title":"Tuning Properties for Blood-Brain Barrier Permeation: A Statistics-Based Analysis","volume":"11","author":"Dichiara","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/ijms25010192","article-title":"Principal Component Analysis (PCA) of Molecular Descriptors for Improving Permeation through the Blood-Brain Barrier of Quercetin Analogues","volume":"25","author":"Pavlovi\u0107","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101760_bib28","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/bi00172a006","article-title":"Delta-sleep-inducing peptide: solution conformational studies of a membrane-permeable peptide","volume":"33","author":"Gray","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2024.101760_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1021\/jm00180a022","article-title":"Relationship of octanol\/water partition coefficient and molecular weight to rat brain capillary permeability","volume":"23","author":"Levin","year":"1980","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.xcrm.2024.101760_bib30","first-page":"1308","article-title":"Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS","volume":"87","author":"Boado","year":"1998","journal-title":"J.\u00a0Pharmacol. Sci. (Tokyo, Jpn.)"},{"key":"10.1016\/j.xcrm.2024.101760_bib31","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/S0196-9781(99)00127-8","article-title":"The effect of halogenation on blood-brain barrier permeability of a novel peptide drug","volume":"20","author":"Gentry","year":"1999","journal-title":"Peptides"},{"key":"10.1016\/j.xcrm.2024.101760_bib32","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0022-3565(25)20489-X","article-title":"Distribution and analgesia of [3H] [D-Pen2, D-Pen5]enkephalin and two halogenated analogs after intravenous administration","volume":"259","author":"Weber","year":"1991","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2024.101760_bib33","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0165-5728(01)00256-9","article-title":"Changing the chemokine gradient: CINC1 crosses the blood-brain barrier","volume":"115","author":"Pan","year":"2001","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.xcrm.2024.101760_bib34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0304-3959(89)90118-8","article-title":"Intrathecal opioids, potency and lipophilicity","volume":"36","author":"McQuay","year":"1989","journal-title":"Pain"},{"key":"10.1016\/j.xcrm.2024.101760_bib35","series-title":"The Use of Intracerebral Microdialysis to Study the Blood-Brain Barrier Transport Characteristics of Drugs (thesis, Leiden\/Amsterdam Center for Drug Research)","first-page":"93","article-title":"Application of intracerebral microdialysis to study regional distribution kinetics of atenolol and acetaminophen in rat brain","author":"de Lange","year":"1993"},{"key":"10.1016\/j.xcrm.2024.101760_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/er.2002-0029","article-title":"Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin","volume":"25","author":"van der Lely","year":"2004","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1124\/jpet.102.034827","article-title":"Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure","volume":"302","author":"Banks","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2024.101760_bib38","article-title":"Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases","author":"Rhea","year":"2023","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.xcrm.2024.101760_bib39","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1073\/pnas.86.2.695","article-title":"Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites","volume":"86","author":"Cordon-Cardo","year":"1989","journal-title":"Proc. Natl. Acad Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101760_bib40","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1172\/JCI118699","article-title":"P-glycoproteinin the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs","volume":"97","author":"Schinkel","year":"1996","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101760_bib41","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1023\/B:PHAM.0000045241.26925.8b","article-title":"Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice","volume":"21","author":"Kalvass","year":"2004","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.xcrm.2024.101760_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/00008571-200111000-00012","article-title":"Ivermectin sensitivity is associated with a deletion mutation of the mdr1 gene","volume":"11","author":"Mealey","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.xcrm.2024.101760_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101760_bib44","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1159\/000110445","article-title":"TNF activates MDR1 (P-glycoprotein) in cerebral microvascular endothelial cells","volume":"20","author":"Yu","year":"2007","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.xcrm.2024.101760_bib45","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.301.1.7","article-title":"Role of multidrug transporters in pharmacoresistance to antiepileptic drugs","volume":"30","author":"Loscher","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2024.101760_bib46","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/dmd.30.3.231","article-title":"Endomorphins, Met-enkephalin, Tyr-MIF-1 and the P-glycoprotein efflux system","volume":"30","author":"Kastin","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.xcrm.2024.101760_bib47","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI25247","article-title":"P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model","volume":"115","author":"Cirrito","year":"2005","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101760_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.3233\/JAD-2009-1074","article-title":"Testing the neurovascular hypothesis of Alzheimer's Disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition","volume":"17","author":"Jaeger","year":"2009","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.xcrm.2024.101760_bib49","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/neu.480250103","article-title":"A putative nicotine pump at the metabolic blood-brain barrier of the tobacco hornworm","volume":"25","author":"Murray","year":"1994","journal-title":"J.\u00a0Neurobiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib50","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.addr.2018.04.009","article-title":"Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics","volume":"135","author":"Pan","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib51","series-title":"Models of Neuropeptide Action","first-page":"108","article-title":"Brain-to-blood transport of peptides and the alcohol withdrawal syndrome","author":"Banks","year":"1994"},{"key":"10.1016\/j.xcrm.2024.101760_bib52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1471-4159.2002.00840.x","article-title":"Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier","volume":"81","author":"Schlachetzki","year":"2002","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.xcrm.2024.101760_bib53","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jalz.2016.04.003","article-title":"CNS tau efflux via exosomes is likey decreased in Parkinson disease but not in Alzheimer disease","volume":"12","author":"Shi","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.xcrm.2024.101760_bib54","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1021\/bi972709x","article-title":"HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter","volume":"37","author":"Lee","year":"1998","journal-title":"Biochemistry"},{"key":"10.1016\/j.xcrm.2024.101760_bib55","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1023\/A:1018932213953","article-title":"In\u00a0vivo and in\u00a0vitro transport of zidovudine (AZT) across the blood-brain barrier and the effects of transport inhibitors","volume":"11","author":"Masereeuw","year":"1994","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.xcrm.2024.101760_bib56","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1113\/expphysiol.1991.sp003516","article-title":"Osmotic-hypertensive opening of the blood-brain barrier in rats does not necessarily provide access for potassium to cerebral interstitial fluid","volume":"76","author":"Somjen","year":"1991","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2018.11.009","article-title":"Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib","volume":"292","author":"Goutal","year":"2018","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.xcrm.2024.101760_bib58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/mds.25420","article-title":"The history of parkinsonism: descriptions in ancient Indian medical literature","volume":"28","author":"Ovallath","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.xcrm.2024.101760_bib59","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/466S6a","article-title":"Levodopa: the story so far","volume":"466","author":"Abbott","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101760_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1515\/bchm2.1913.88.4.276","article-title":"Dioxyphenylalanin, eine neue Aminos\u00e4ure aus Vicia faba","volume":"88","author":"Guggenheim","year":"1913","journal-title":"Hoppe-Seyler's Z. f\u00fcr Physiol. Chem."},{"key":"10.1016\/j.xcrm.2024.101760_bib61","first-page":"554","article-title":"Synthesis of DL-3 : 4-Dihydroxyphenylalanine","volume":"99","author":"Funk","year":"1911","journal-title":"J.\u00a0Chem. Soc. Trans."},{"key":"10.1016\/j.xcrm.2024.101760_bib62","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJM196702162760703","article-title":"Aromatic amino acids and modification of parkinsonism","volume":"276","author":"Cotzias","year":"1967","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib63","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","article-title":"Treatment of parkinsonism with levodopa","volume":"21","author":"Yahr","year":"1969","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.xcrm.2024.101760_bib64","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2024.101760_bib65","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0005-2736(75)90347-8","article-title":"Kinetic analysis of blood-brain barrier transport of amino acids","volume":"401","author":"Pardridge","year":"1975","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.xcrm.2024.101760_bib66","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1152\/ajplegacy.1976.230.1.94","article-title":"Amino acid assignment to one of three blood-brain barrier amino acid carriers","volume":"230","author":"Oldendorf","year":"1976","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib67","doi-asserted-by":"crossref","first-page":"S497","DOI":"10.1002\/mds.22028","article-title":"The history of dopamine and levodopa in the treatment of Parkinson's disease","volume":"23","author":"Fahn","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.xcrm.2024.101760_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23010040","article-title":"Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease","volume":"23","author":"Haddad","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.xcrm.2024.101760_bib69","doi-asserted-by":"crossref","first-page":"12079","DOI":"10.1073\/pnas.96.21.12079","article-title":"Selective expression of the large neutral amino acid transporter at the blood-brain barrier","volume":"96","author":"Boado","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101760_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107964","article-title":"Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics","volume":"230","author":"Kanai","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2024.101760_bib71","doi-asserted-by":"crossref","first-page":"1539S","DOI":"10.1093\/jn\/135.6.1539S","article-title":"Branched-chain amino acids and brain function","volume":"135","author":"Fernstrom","year":"2005","journal-title":"J.\u00a0Nutr."},{"key":"10.1016\/j.xcrm.2024.101760_bib72","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10545-010-9216-1","article-title":"Large neutral amino acids in the treatment of PKU: from theory to practice","volume":"33","author":"van Spronsen","year":"2010","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.xcrm.2024.101760_bib73","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41380-018-0076-7","article-title":"Leucine competitively inhibits blood-to-brain kynurenine transport and prevents lipopolysacchride-induced depression-like behavior in mice","volume":"24","author":"Walker","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.xcrm.2024.101760_bib74","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1126\/science.173.3992.149","article-title":"Brain serotonin content: physiological dependence on plasma tryptophan levels","volume":"173","author":"Fernstrom","year":"1971","journal-title":"Science (Washington DC)"},{"key":"10.1016\/j.xcrm.2024.101760_bib75","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2017.03.034","article-title":"Pyrilamine-sensitive proton-coupled organic cation (H(+)\/OC) antiporter for brain-specific drug delivery","volume":"254","author":"Wang","year":"2017","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.xcrm.2024.101760_bib76","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/1471-2377-9-S1-S3","article-title":"Characteristics of compounds that cross the blood-brain barrier","volume":"9","author":"Banks","year":"2009","journal-title":"BMC Neurol."},{"key":"10.1016\/j.xcrm.2024.101760_bib77","first-page":"79","article-title":"Peptide transport across the blood-brain barrier","volume":"61","author":"Kastin","year":"2003","journal-title":"Prog. Drug Res."},{"key":"10.1016\/j.xcrm.2024.101760_bib78","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0196-9781(97)00231-3","article-title":"Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin","volume":"18","author":"Banks","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.xcrm.2024.101760_bib79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.31491\/APT.2022.12.100","article-title":"Evidence for an alternative insulin transporter at the blood-brain barrier","volume":"4","author":"Banks","year":"2022","journal-title":"Aging Pathobiol. Ther."},{"key":"10.1016\/j.xcrm.2024.101760_bib80","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0024-3205(87)90606-0","article-title":"Saturable transport of peptides across the blood-brain barrier","volume":"41","author":"Banks","year":"1987","journal-title":"Life Sci."},{"key":"10.1016\/j.xcrm.2024.101760_bib81","article-title":"Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier","volume":"8","author":"Li","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2024.101760_bib82","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/brain\/awac393","article-title":"Editing a gateway for cell therapy across the blood-brain barrier","volume":"146","author":"Ach\u00f3n Buil","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.xcrm.2024.101760_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1359","article-title":"Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys","volume":"12","author":"Kariolis","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib84","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1038\/s41467-023-40681-4","article-title":"CD98hc is a target for brain delivery of biotherapeutics","volume":"14","author":"Chew","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101760_bib85","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1074\/jbc.274.5.3009","article-title":"4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer","volume":"274","author":"Nakamura","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.xcrm.2024.101760_bib86","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the Brainshuttle\u2122 amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"mAbs"},{"key":"10.1016\/j.xcrm.2024.101760_bib87","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer's disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib88","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2024.101760_bib89","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-008-9055-2","article-title":"CNS delivery via adsorptive transcytosis","volume":"10","author":"Herve","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.xcrm.2024.101760_bib90","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/15353702221080745","article-title":"Transcellular routes of blood-brain barrier disruption","volume":"247","author":"Erickson","year":"2022","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib91","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2174\/138161208784705423","article-title":"Blood-brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides","volume":"14","author":"Kastin","year":"2008","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.xcrm.2024.101760_bib92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(96)03173-X","article-title":"Decreased cerebrospinal-fluid\/serum leptin ratio in obesity: a possible mechanism for leptin resistance","volume":"348","author":"Caro","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2024.101760_bib93","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fnagi.2019.00196","article-title":"Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier","volume":"11","author":"Erd\u0151","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12987-023-00481-w","article-title":"Neurovascular unit disruption and blood-brain barrier leakage in MCT8 deficiency","volume":"20","author":"Guill\u00e9n-Yunta","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.xcrm.2024.101760_bib95","doi-asserted-by":"crossref","first-page":"12658","DOI":"10.1073\/pnas.0405042101","article-title":"Developmentally regulated mannose 6-phosphate receptor-mediated transport of a lysosomal enzyme across the blood-brain barrier","volume":"101","author":"Urayama","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101760_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039565","article-title":"Human immunodeficiency virus-1 uses the mannose-6-phosphate receptor to cross the blood-brain barrier","volume":"7","author":"Dohgu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101760_bib97","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1056\/NEJM199109053251006","article-title":"Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay","volume":"325","author":"De Vivo","year":"1991","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib98","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0006-8993(01)02242-9","article-title":"Enhanced leptin transport across the blood-brain barrier by alpha1-adrenergic agents","volume":"899","author":"Banks","year":"2001","journal-title":"Brain Res."},{"key":"10.1016\/j.xcrm.2024.101760_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142347","article-title":"Alpha adrenergic induction of transport of lysosomal enzyme across the blood-brain barrier","volume":"10","author":"Urayama","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.xcrm.2024.101760_bib100","series-title":"Blood Brain Barrier in Physiology and Medicine","author":"Rapoport","year":"1976"},{"key":"10.1016\/j.xcrm.2024.101760_bib101","first-page":"E124","article-title":"Blood-brain barrier transport of neuropeptides: analysis with a metabolically stable dermorphin analogue","volume":"267","author":"Samii","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib102","first-page":"R581","article-title":"Dynamics of interstitial and intracellular pH in evolving brain infarct","volume":"260","author":"Nedergaard","year":"1991","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/13550280152403236","article-title":"Virus receptors in the human central nervous system","volume":"7","author":"Schweighardt","year":"2001","journal-title":"J.\u00a0Neurovirol."},{"key":"10.1016\/j.xcrm.2024.101760_bib104","first-page":"43","article-title":"Inhibition of three alphaherpesviruses (herpes simplex 1 and 2 and pseudorabies virus) by heparin, heparan and other sulfated polyelectrolytes","volume":"27","author":"Ramos-Kuri","year":"1996","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.xcrm.2024.101760_bib105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj2180001","article-title":"The entry of enveloped viruses into cells by endocytosis","volume":"218","author":"Marsh","year":"1984","journal-title":"Biochem. J."},{"key":"10.1016\/j.xcrm.2024.101760_bib106","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00126334-199101000-00008","article-title":"Transmission of human immunodeficiency virus from monocytes to epithelia","volume":"4","author":"Bourinbaiar","year":"1991","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.xcrm.2024.101760_bib107","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.xcrm.2024.101760_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35976-2","article-title":"Brain-Specific Ultrastructure of Capillary Endothelial Glycocalyx and Its Possible Contribution for Blood Brain Barrier","volume":"8","author":"Ando","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2024.101760_bib109","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/jpet.122.001380","article-title":"Transport of the pro-inflammatory chemokines CCL2 (MCP-1) and CCL5 (RANTES) across the intact mouse blood-brain barrier is inhibited by heparin and eprodisate and increased with systemic inflammation","volume":"384","author":"Quaranta","year":"2023","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.xcrm.2024.101760_bib110","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1007\/s00125-023-05906-7","article-title":"The expanding incretin universe: from basic biology to clinical translation","volume":"66","author":"Drucker","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.xcrm.2024.101760_bib111","first-page":"377","article-title":"The glucagon-like peptides: a double-edged therapeutic sword? Trends in Pharmacol","volume":"24","author":"Perry","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101760_bib112","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02183-16","article-title":"Trojan Horse Transit Contributes to Blood-Brain Barrier Crossing of a Eukaryotic Pathogen","volume":"8","author":"Santiago-Tirado","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.xcrm.2024.101760_bib113","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41565-023-01419-x","article-title":"Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain","volume":"18","author":"Chuapoco","year":"2023","journal-title":"Nat.\u00a0Nanotechnol."},{"key":"10.1016\/j.xcrm.2024.101760_bib114","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-023-38582-7","article-title":"Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101760_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/v13102021","article-title":"Spike Proteins of SARS-CoV-2 Induce Pathological Changes in Molecular Delivery and Metabolic Function in the Brain Endothelial Cells","volume":"13","author":"Kim","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.xcrm.2024.101760_bib116","article-title":"Brain blood vessel autoantibodies in patients with NMDA and GABA(A) receptor encephalitis: identification of unconventional Myosin-X as target antigen","volume":"17","author":"Li","year":"2023","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib117","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000117103","article-title":"Endothelial cell\u00a0damage in sarcoidosis and neurosarcoidosis: autoantibodies to endothelial cells","volume":"35","author":"Tsukada","year":"1995","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.xcrm.2024.101760_bib118","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.2174\/1381612043384862","article-title":"Are the extracellular [correction of extracelluar] pathways a conduit for the delivery of therapeutics to the brain?","volume":"10","author":"Banks","year":"2004","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.xcrm.2024.101760_bib119","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/exnr.1993.1059","article-title":"Serum proteins bypass the blood-brain barrier for extracellular entry to the central nervous system","volume":"120","author":"Broadwell","year":"1993","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.xcrm.2024.101760_bib120","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"St-Amour","year":"2013","journal-title":"J.\u00a0Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.xcrm.2024.101760_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2023.1089005","article-title":"Preserved blood-brain barrier and neurovascular coupling in female 5xFAD model of Alzheimer's disease","volume":"15","author":"Zhukov","year":"2023","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib122","first-page":"171","article-title":"A case of cerebral tumor--the surgical treatment","volume":"24","author":"Bennett","year":"1974","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2024.101760_bib123","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.wneu.2023.11.130","article-title":"Sir Rickman John Godlee-Contributions in Addition to His 1884 Tumor Resection, A Review","volume":"183","author":"Shen","year":"2024","journal-title":"World Neurosurg."},{"key":"10.1016\/j.xcrm.2024.101760_bib124","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101760_bib125","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/bs.apha.2014.06.002","article-title":"Delivery of chemotherapeutics across the blood-brain barrier: challenges and advances","volume":"71","author":"Doolittle","year":"2014","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.xcrm.2024.101760_bib126","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/1097-0142(197401)33:1<19::AID-CNCR2820330107>3.0.CO;2-M","article-title":"Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule","volume":"33","author":"Benjamin","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.xcrm.2024.101760_bib127","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S1359-6446(00)01643-3","article-title":"Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2)","volume":"6","author":"Kusuhara","year":"2001","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.xcrm.2024.101760_bib128","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1158\/1078-0432.CCR-10-1564","article-title":"Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer","volume":"16","author":"Lockman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101760_bib129","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1748-1716.1945.tb00297.x","article-title":"An Experimental Study of Disorders in the Permeability of the Cerebral Vessels (\u201cthe Blood-Brain-Barrier\u201d) Produced by Chemical and Physico-chemical Agents","volume":"10","author":"Broman","year":"2008","journal-title":"Acta Physiol. Scand."},{"key":"10.1016\/j.xcrm.2024.101760_bib130","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.173.4001.1026","article-title":"Reversible osmotic opening of the blood-brain barrier","volume":"173","author":"Rapoport","year":"1971","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101760_bib131","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/cne.901850307","article-title":"Opening of tight junctions in cerebral endothelium. I. Effect of hyperosmolar mannitol infused through the internal carotid artery","volume":"185","author":"Nagy","year":"1979","journal-title":"J.\u00a0Comp. Neurol."},{"key":"10.1016\/j.xcrm.2024.101760_bib132","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1172\/JCI109509","article-title":"Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery","volume":"64","author":"Neuwelt","year":"1979","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.xcrm.2024.101760_bib133","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2021915118","article-title":"Blood-brain barrier opening by intracarotid artery hyperosmolar mannitol induces sterile inflammatory and innate immune responses","volume":"118","author":"Burks","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101760_bib134","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00688236","article-title":"Structural changes in the rat brain after carotid infusions of hyperosmolar solutions. An electron microscopic study","volume":"77","author":"Salahuddin","year":"1988","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.xcrm.2024.101760_bib135","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/ANA.0b013e31815d5f1f","article-title":"Perioperative complications of blood brain barrier disruption under general anesthesia: a retrospective review","volume":"20","author":"Elkassabany","year":"2008","journal-title":"J.\u00a0Neurosurg. Anesthesiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061283","article-title":"A Historical Review of Brain Drug Delivery","volume":"14","author":"Pardridge","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.xcrm.2024.101760_bib137","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1073\/pnas.1614777114","article-title":"Disrupting the blood-brain barrier by focused ultrasound induces sterile inflammation","volume":"114","author":"Kovacs","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101760_bib138","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ultras.2009.08.015","article-title":"MRI-guided focused ultrasound treatments","volume":"50","author":"Hynynen","year":"2010","journal-title":"Ultrasonics"},{"key":"10.1016\/j.xcrm.2024.101760_bib139","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1586\/14737175.2015.1028369","article-title":"Focused ultrasound-mediated drug delivery through the blood-brain barrier","volume":"15","author":"Burgess","year":"2015","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.xcrm.2024.101760_bib140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3171\/2022.9.JNS221565","article-title":"Focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes","volume":"139","author":"Rezai","year":"2023","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.xcrm.2024.101760_bib141","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMoa2308719","article-title":"Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease","volume":"390","author":"Rezai","year":"2024","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib142","first-page":"217","article-title":"A physiological barrier distal to the anatomic blood-brain barrier in a model of transvascular delivery","volume":"20","author":"Muldoon","year":"1999","journal-title":"AJNR. Am. J. Neuroradiol."},{"key":"10.1016\/j.xcrm.2024.101760_bib143","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0304-3940(94)91020-0","article-title":"Neurotoxicity of albumin in\u00a0vivo","volume":"167","author":"Hassel","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.xcrm.2024.101760_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8283","article-title":"Blood-brain barrier dysfunction in aging induces hyperactivation of TGFbeta signaling and chronic yet reversible neural dysfunction","volume":"11","author":"Senatorov","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101760_bib145","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.2174\/1381612822666160617112111","article-title":"Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective","volume":"22","author":"Ahmad","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.xcrm.2024.101760_bib146","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nrn.2015.27","article-title":"Autoimmune synaptopathies","volume":"17","author":"Crisp","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.xcrm.2024.101760_bib147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalistis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J.\u00a0Neuroimmunol."},{"key":"10.1016\/j.xcrm.2024.101760_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043895","article-title":"Alzheimer's Disease: A Brief History of Immunotherapies Targeting Amyloid \u03b2","volume":"24","author":"Vogt","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.xcrm.2024.101760_bib149","article-title":"Fluid biomarkers of the neurovascular unit in cerebrovascular disease and vascular cognitive disorders: A systematic review and meta-analysis","volume":"6","author":"Hansra","year":"2024","journal-title":"Cereb. Circ. Cogn. Behav."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T04:13:54Z","timestamp":1758687234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124004907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":149,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2666379124004907"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101760","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101760"}}